drugset / Trial / NCT00150215

A First In Human Study Of PF-00184562 In Healthy Volunteers

NCT00150215

Phase 1 Completed 18 enrolled Pfizer PPD Development, LP · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purposes of this study are: * To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and * To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.

Timeline

Start
2005-07
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule
Subject PF-00184562 Unknown Oral

Indications